Innovation Pharmaceuticals Inc (IPIX)

[frrol]

They're all a risk of failure of course. Management saw the P risk heighten when the interim results were to be evaluated. We saw indications of this when P fell back in the pipeline presentations.

As for B-OM "low initial payments but higher royalties", B-UP had low initial payments. If it has low(er) royalties than what you suppose for B-OM, by your (apparent) reasoning that is because it has more certain market potential. And that doesn't make sense, the reasoning crumbles.

The most important thing is we get a deal for B-OM. It's merits and potential will be reflected in the terms. I think our management gets the best deals it can. Hopefully a B-OM deal would be a bit richer, we'll see.

Anyway, what do you think about the chances of a B-OM deal before the Q? That's what I've been inquiring from others.